Indian restaurant fined almost £44,000 after customer with nut allergy suffers severe allergic reaction
An Indian restaurant and takeaway has been fined almost £44,000 after a customer suffered an allergic reaction and needed hospital treatment.
The customer, who has a nut allergy, experienced a serious reaction after eating a meal containing undeclared allergens from Javitri, at 112 High Street in Uxbridge.
They filed a complaint with Hillingdon Council, prompting food hygiene and safety officers to investigate the premises on June 26 last year, where they identified 'significant failings' in the restaurant's allergen information and control measures.
JR Uxbridge Ltd, which operates Javitri, pleaded guilty to five offences at Uxbridge Magistrates' Court on Tuesday, April 22.
The company was fined £35,000 and required to pay a victim surcharge of £5,000 and the council's prosecution costs of £3,816.
During the investigation, council officers found a string of failures in the management of allergens, including nuts stored incorrectly in the kitchen, incomplete menu descriptions and uncertainty regarding recipes despite staff having undertaken the Food Standards Agency's allergen training earlier that month.
Officers provided the restaurant with a detailed report outlining the required improvements, including identifying the ingredients and allergens in every dish.
A follow up inspection on July 16 found little improvement had been made, and subsequently an improvement notice was served, requiring accurate allergen information to be provided to the council by 13 August.
Officers revisited the restaurant on August 14 and were presented with an allergen menu, meant for customers, that was confusing and still contained inaccurate information which would still place anyone with allergies at risk.
The business was ordered to send a revised menu with clear allergen information to the council by August 21.
The documents received were inadequate and despite multiple requests for clarification, no further revisions were received.
Councillor Eddie Lavery said: 'It's a legal responsibility for all food businesses to provide accurate allergen information to customers and ensure what they are producing and selling is safe.
'This case shows that failing to do so can have severe consequences for people with allergies.
'Our food standards team works hard to protect residents from harm through routine inspections, educating businesses, serving improvement notices and if required taking legal action against businesses that neglect their responsibilities.
'Let this be a warning to businesses that they need to operate in line with regulations or they will be fined.'
JR Uxbridge Ltd pleaded guilty to five offences in breach of health and safety at work, food information, and food safety and hygiene regulations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
9 hours ago
- Forbes
The Future Of Healthcare Is Collaborative—And AI Is The Catalyst
Collaboration and AI in Indian health care A quiet revolution is underway in the heart of a radiology lab at Apollo Hospitals in Chennai, India. Artificial intelligence is scanning high-resolution images, flagging anomalies, reducing the time for diagnosis, and improving accuracy. But what makes this advancement so powerful isn't just the algorithm behind it. It's the collaboration between a hospital, a tech company, and a university that makes AI innovation sustainable, scalable, and relevant to India's complex healthcare landscape. Across India, a new model of digital health transformation is emerging, one where partnerships are as crucial as platforms. For a country grappling with massive disparities in healthcare access and delivery, this shift couldn't be more timely. These are the observations and conclusions from my peer, Dr. Priyanka Shrivastava, who is a Professor of Marketing & Analytics at Hult International Business School and an Executive Fellow at The Digital Economist. India's healthcare system faces deep challenges: a rapidly growing population, stark urban-rural divides, a chronic shortage of medical professionals, and overstretched public infrastructure. While the proliferation of health-tech startups has brought promise, much of the innovation remains confined to urban pockets or pilot projects. AI detects disease, streamlines diagnosis, and personalizes treatment. Tools like AI-powered nutrition coaches (HealthifyMe's Ria) and automated diagnostic assistants (such as those used by Aindra or Columbia Asia Hospital) are transforming the delivery of healthcare. Yet, these tools often encounter barriers due to a lack of interoperability, fragmented data systems, regulatory uncertainty, and resistance from overworked staff who fear that AI might be more of a disruption than an aid. Technology alone cannot fix healthcare. But technology plus collaboration just might. In a recent study, Dr. Shrivastava and her colleagues surveyed 300 healthcare professionals across 50 institutions and held in-depth interviews with doctors, technologists, and policymakers. The results were striking: institutions with strong cross-sector collaborations consistently showed higher and more sustained AI adoption. Three core insights emerged: Urban hospitals often have access to advanced technology and data, whereas rural clinics often lack even basic diagnostic capabilities. But when these entities partner via telemedicine links, shared platforms, or co-funding arrangements, AI can extend its reach. For example, Apollo's AI systems, when linked with satellite clinics, enable faster referrals and better triage in underserved regions. Resistance to AI isn't irrational—it often stems from a lack of understanding. The study found that joint workshops, where doctors and engineers co-learned and co-created, built buy-in from healthcare workers. When staff are trained with the tools and understand how they were developed, they are far more likely to embrace them. AI isn't plug-and-play. It requires regular updates, feedback loops, and cultural alignment. Institutions that formalized collaboration through MOUs, shared R&D labs, or co-published studies were more likely to sustain AI programs over the long term. Apollo's AI-driven radiology initiative in Chennai is a textbook example. Faced with long diagnosis times and overburdened radiologists, the hospital sought a solution. Instead of simply buying an off-the-shelf AI tool, Apollo co-developed one with a university, providing algorithm expertise, and a startup delivering the technical infrastructure. Doctors and developers worked side by side. The result? Diagnosis time dropped by 30%, and accuracy improved by 15%. Radiologists weren't replaced—they were enhanced, with AI acting as a second pair of eyes. Continuous training and feedback ensured the system evolved with practice. This wasn't a one-off deployment. It was an ecosystem. And that made all the difference. While Apollo represents a private success, the public sector isn't far behind. India's eSanjeevani platform, which added AI-supported teleconsultation features during the pandemic, saw a 40% increase in rural usage. This shows that with the right support and scale, AI can democratize access to care. The National Digital Health Mission is another promising initiative. If executed well—with strong data privacy frameworks and open APIs—it can offer a common layer for innovation. Startups can plug into public records; government hospitals can access AI-enabled diagnostics; researchers can draw insights from anonymized data. But for this to happen, policymakers must prioritize collaboration frameworks just as much as digital infrastructure. As India enters a defining decade for health innovation, here are four actionable takeaways from the research: Tax breaks, innovation grants, and pilot funding for joint ventures in AI health can catalyze adoption. Startups gain credibility and scale; public hospitals get access to frontier tech. Set up AI literacy programs for frontline health workers. Encourage interdisciplinary training so doctors, nurses, and tech teams speak a common language. A national framework on health data interoperability is overdue. Without this, AI solutions cannot scale beyond one institution. Build trust through consent-driven, encrypted data-sharing norms. Mandate impact audits for all health AI deployments—measuring not just tech efficiency, but patient outcomes, staff satisfaction, and system-level equity. The most inspiring part of this story? AI in Indian healthcare isn't being driven solely by top-down mandates or Silicon Valley imports. It's being shaped organically by Indian doctors, engineers, policy thinkers, and entrepreneurs who are joining forces. This pluralistic model with many voices but one mission could well become a template for emerging economies around the world. In a landscape where access to a doctor can mean the difference between life and death, AI's potential is undeniable. But its success will depend on something far more human: our ability to collaborate. The most transformative technology for health care is not an algorithm. It is the alignment of purpose, people, vision, and AI through collaboration.
Business Upturn
a day ago
- Business Upturn
ROOH Officially Opens in Toronto With Focus on Health-Conscious Indian Cuisine
ROOH has officially launched in downtown Toronto, offering a health-focused Indian dining experience centered on nutrition, sustainability, and regional flavors. The new restaurant builds on Bar Goa's model by applying research-based cooking and transparent sourcing to modern fine dining. Photo Courtesy of ROOH TORONTO, June 10, 2025 (GLOBE NEWSWIRE) — ROOH has opened its doors at 633 College Street in Toronto, offering a menu centered on sustainability, nutrition, and regionally inspired Indian flavors. The restaurant represents the second concept from the team behind Bar Goa, recognized in the 2024 Michelin Guide. ROOH offers a distinct alternative to traditional Indian dining by combining public health principles with acceptable dining practices. The venue features a seasonally adjusted menu built around transparent sourcing and scientific cooking practices to preserve nutrients and support long-term wellness. The kitchen team follows structured methods informed by behavioral science and nutritional research. Staff receive ingredient sourcing, food science, and guest communication training, supporting the restaurant's broader mission to connect hospitality with public health goals. ROOH expands on Bar Goa's health-forward model by drawing from culinary traditions across India. The menu features seasonal vegetables, fermented ingredients, and spice blends supported by nutrition studies. The team develops dishes by drawing on regional culinary research and partnering with local ingredient suppliers. 'We apply food science alongside tradition to raise the profile of regional Indian cuisine,' says founder Dr. Jayadeep Patra. 'This method offers a new take that fits today's changing dining scene.' The restaurant's model responds to increasing demand for meals combining rich flavor and wellness alignment. ROOH's operational structure reflects a long-term vision to integrate evidence-based practices into modern dining experiences. Together with its sister restaurant, Bar Goa, ROOH continues to evolve a food philosophy rooted in sustainability, science, and culturally grounded cuisine. About ROOH and Bar Goa ROOH and Bar Goa are Indian fine-dining restaurants based in Toronto. They were built on the work of public health scientist and restaurateur Dr. Jayadeep Patra. The Michelin Guide recognized Bar Goa in 2024 for its health-conscious coastal Indian cuisine. ROOH builds on this model by offering seasonal, regional Indian dishes shaped by nutritional research and sustainability practices. Both restaurants highlight transparency, ingredient integrity, and a hospitality approach informed by science. Contact information: Contact Person's Name: Dr. Jayadeep Patra Organization / Company: ROOH and Bar Goa Company website: | Contact Email Address: [email protected] City, Province, Country: 633 College St, Toronto, Ontario, Canada A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
a day ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need, and to capitalize on the immense commercial potential of our pipeline, we need to think prudently and practically about our manufacturing approach. In the short term, our manufacturing demands are almost 200 drug products per day, and this may increase as CAR-T cell therapies move closer to front line treatment. The only practical way for us to industrialize our production and produce a supply of drug product commensurate with total patient demand is to transition to G-Rex," said Dr. Lakshmikanth Gandikota, Head of R&D, MSAT Intellectual Property, and Translational Research, at Immuneel Therapeutics Limited. "We are extremely impressed by the speed, resourcefulness, creativity, discipline, and entrepreneurialism of the team at Immuneel and are happy to see that India, as a whole, is making significant strides toward CAR-T availability. It gives us a great sense of satisfaction to be in a position to help bring hope to cancer patients in India, one G-Rex at a time," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of Immuneel's G-Rex Grant, they will perform process development, qualification, and validation of a G-Rex based CAR-T cell therapy production approach to dramatically increase the throughput capacity of their state-of-the-art, 12,000 square foot GMP facility. Located in Bengaluru and opened in 2021, Immuneel's Integrated Cell Therapy Development and Manufacturing Facility was the first of its kind in India and is designed to bring breakthrough cell and gene therapies to millions of patients in India. Lastly, Immuneel's G-Rex Grant will support the requisite comparability studies necessary to support a post-CAR-T approval manufacturing change from their difficult to scale low throughput all-in-one manufacturing equipment to a much simpler high throughput G-Rex centric approach. The high popularity of ScaleReady's G-Rex Grant Program led ScaleReady to increase award funds from the original amount of $20M to a total of $30M directed towards saving recipients significant time and money by expediting the path to optimized cell and gene-modified cell therapy manufacturing. Two hundred grants have already been awarded with over 50 new applications in the queue. Each G-Rex Grant recipient can obtain up to $300,000 and gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact info@ About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized immunotherapies, for cancer patients in India. As a research-driven and fully integrated organization, Immuneel is dedicated to making next-generation cancer treatments accessible and affordable, with a strong focus on innovation and clinical impact. The company's mission is to democratize advanced therapies by developing and commercializing breakthrough solutions tailored to the needs of Indian patients. As part of its growing portfolio, Immuneel has licensed and commercialized Qartemi® (varnimcabtagene autoleucel), a CD19 CAR-T cell therapy approved by India's Central Drugs Standard Control Organization (CDSCO) for the treatment of adult B-cell non-Hodgkin lymphoma a novel therapy for blood cancer, further demonstrating its commitment to transforming cancer care in India. Immuneel has a robust pipeline of CAR-T therapies for various indications in Oncology and AutoImmune diseases For more information, please visit: View original content to download multimedia: SOURCE Bio-Techne Corporation
